FOXC2 and invasive breast carcinoma: Moreover, the significance of this observation is reiterated by our finding that PLK1 and the FOXC2 potential target CDK1 mRNA collectively predict poor DRFS among invasive breast cancer patients after taxane-anthracycline chemotherapy39.